Eli Lilly and Company (NYSE:LLY) executives said the drugmaker started 2026 with “a strong start,” pointing to sharp first-quarter revenue growth, continued demand for its incretin medicines, a newly ...

Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...

European Commission grants authorization in adults and children 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, May 01, 2026 (GLOBE ...

Eli Lilly's newly launched oral weight-loss drug, Foundayo, was prescribed 5,612 times in the U.S. in the third week after ...

Nitinotes Ltd., a medical technology company with the first CE-marked automated suturing system designed for endoscopic sleeve ...

Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in the United States—an inflection ...

While scientific studies about obesity and general health are on the rise, a new analysis has determined that more studies are using animal modeling research than human modeling. Dr. Sarah Purcell, an ...

Novo Nordisk inks this deal with OpenAI as the total value of AI partnerships took a 120% YoY uptick between 2024 and 2025.

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

UAE approves Foundayo, a new oral GLP-1 weight-loss pill, raising key questions on cost, insurance coverage and access for obesity patients nationwide.

These foods are the heaviest hitters. While GLP-1 drugs have transformed how many people think about weight loss, the pharmaceuticals are still most effective when paired with those old, familiar ...

A doctor discusses common issues and questions around Foundayo, the oral obesity pill approved by the FDA this week.